Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    chromadex [Lead]
Previous Study | Return to List | Next Study

A Study by ChromaDex to Assess the Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03562468
Recruitment Status : Completed
First Posted : June 19, 2018
Last Update Posted : July 24, 2019
Sponsor:
Collaborator:
Midwest Center for Metabolic and Cardiovascular Research
Information provided by (Responsible Party):
ChromaDex, Inc.

Tracking Information
First Submitted Date  ICMJE May 25, 2018
First Posted Date  ICMJE June 19, 2018
Last Update Posted Date July 24, 2019
Actual Study Start Date  ICMJE June 13, 2018
Actual Primary Completion Date April 26, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 27, 2018)
The primary comparison will be the low dose (300 mg/d nicotinamide riboside) condition to the placebo condition for the change from baseline to the end of each relevant treatment period. [ Time Frame: 8 weeks ]
The primary outcome variable will be the difference between treatments in the change from baseline (defined as visit 2 value for each of the three treatment periods) in executive function measured with the CNS Vital Signs test battery, using the standard score.
Original Primary Outcome Measures  ICMJE
 (submitted: June 8, 2018)
The primary outcome variable will be the difference between the 300 mg NR condition and placebo in the change from baseline in executive function measured with the CNS Vital Signs test battery. [ Time Frame: 8 weeks ]
The executive function measured with the CNS Vital Signs test battery after the 8-week treatment period with nicotinamide riboside (300mg/day) will be compared with baseline. The executive function measured with the CNS Vital Signs test battery after the 8-week treatment period with placebo will be compared with baseline. The primary outcome variable will be the difference between treatments in the change from baseline in executive function measured with the CNS Vital Signs test battery.
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study by ChromaDex to Assess the Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older Adults
Official Title  ICMJE A Randomized, Double-Blind, Crossover Study to Assess the Effects of Nicotinamide Riboside on Cognitive Function, Mood and Sleep in Older Adult Men and Women
Brief Summary The sponsor of this study is ChromaDex, Inc. This is a double-blind, randomized, crossover study to investigate the effects of 300 mg/d and 1000 mg/d TRU NIAGEN (nicotinamide riboside) compared to a placebo control on cognitive function, mood and sleep in men and women over 55 years of age. The trial is managed by Midwest Center for Metabolic and Cardiovascular Research.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:
Treatments will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
The study site will be provided placebo and TRU NIAGEN capsules, each labeled with the protocol number, blinded product code, expiration date, batch number, the statement "For Investigational Use Only" and a space to write the subject's initials, screen and date dispensed.
Primary Purpose: Other
Condition  ICMJE
  • Cognitive Function
  • Mood
  • Sleep
Intervention  ICMJE
  • Dietary Supplement: 300 mg/day of TRU NIAGEN (nicotinamide riboside)
    Treatment with 300 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
    Other Name: Niagen, the active ingredient in TRU NIAGEN
  • Dietary Supplement: 1000 mg/day of TRU NIAGEN (nicotinamide riboside)
    Treatment 1000 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
    Other Name: Niagen, the active ingredient in TRU NIAGEN
  • Dietary Supplement: Placebo
    Treatment with placebo capsules will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    Each subject will be randomly assigned to receive placebo for an 8-week treatment period. Subjects will be instructed to take two capsules (placebo) in the morning with breakfast and two capsules (placebo) in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
    Intervention: Dietary Supplement: Placebo
  • Experimental: TRU NIAGEN (nicotinamide riboside) 300 mg/day
    Each subject will be randomly assigned to receive 300 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
    Intervention: Dietary Supplement: 300 mg/day of TRU NIAGEN (nicotinamide riboside)
  • Experimental: TRU NIAGEN (nicotinamide riboside) 1000 mg/day
    Each subject will be randomly assigned to receive 1000 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
    Intervention: Dietary Supplement: 1000 mg/day of TRU NIAGEN (nicotinamide riboside)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 8, 2018)
40
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE April 26, 2019
Actual Primary Completion Date April 26, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subject is male or female, ≥55 years of age.
  2. Subject has a BMI of 18.50 to 34.99 kg/m2.
  3. Subject has a score of ≥80 on executive function at screening. One re-test will be allowed for subjects who require additional instruction on the CNS VS test battery.
  4. Subject is willing to maintain usual diet and physical activity patterns.
  5. Subject has no plans to change smoking habits during the study period.
  6. Subject is willing to limit alcohol consumption to no more than one serving of alcohol per day (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor) and will abstain from consuming 2 h prior to retiring for the evening for the duration of the study.
  7. Subject is willing to limit consumption of caffeine-containing beverages/foods/products to no more than 400 mg daily, with all caffeine consumption occurring prior to 6 pm.
  8. Subject is willing to fast (8 - 15 h, target 10 h, water only) prior to each clinic visit.
  9. Subject has no difficulties swallowing capsules.
  10. Subject is willing and able to attend all clinic visits.
  11. Subject understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator and is willing to complete study procedures.

Exclusion Criteria:

  1. Individual has history or presence of a clinically significant (in the opinion of the Investigator) psychiatric disorder or neurologic disease including epilepsy, cerebrovascular disturbance or traumatic injury.
  2. Individual has a history of diagnosed clinical depression in the prior 2 years, or a score ≥20 (defined as moderate-to-severe depression) on the Beck Depression Inventory-II administered at visit 1 (week -1).
  3. Individual is currently diagnosed with dementia and/or has a score <24 on the Mini Mental State Questionnaire administered at visit 1 (week -1).
  4. Uncorrected abnormal vision that in the opinion of the Investigator would impair the subject's ability to complete the computerized testing (including but not limited to nearsightedness, farsightedness, and color blindness).
  5. Individual has a clinically important active endocrine, cardiovascular, renal, hepatic, pulmonary, pancreatic, neurologic or biliary disorder.
  6. Individual has a history of a cardiovascular event or revascularization procedure within 6 months of visit 1 (week -1).
  7. Individual has a diagnosis of type I diabetes mellitus. Type 2 diabetes mellitus is excluded if the individual has experienced initiation of or a dosage change in diabetes medication(s) within 2 months of visit 1 (week -1), or has significant co-morbidities as determined by the study physician.
  8. Insulin for the treatment of Type I or Type 2 diabetes mellitus is exclusionary.
  9. Individual has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg).
  10. Individual has a recent history (prior 5 years) or the presence of cancer other than non-melanoma skin cancer.
  11. Individual has a history or presence of a chronic pain condition requiring regular use of opioid therapy.
  12. Individual has a recent history or strong potential for drug or alcohol abuse defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1 ½ oz distilled spirits).
  13. Individual has a history of unconventional sleep patterns (e.g., night shift) or chronic insomnia (at least 3 d/week over the past month), a diagnosed sleep disorder, or a chronic medical condition with the potential to impact energy/fatigue levels.
  14. Individuals taking any form of niacin >25 mg/d and any use of nicotinamide riboside within 2 weeks of visit 1 (week -1).
  15. Individual is a heavy consumer of caffeinated beverages (>400 mg/d within 2 weeks of visit 1).
  16. Individual has a history of using psychotropic medications (including antidepressants and tranquilizers), stimulant medications, and/or narcotics within 4 weeks of visit 1 (week -1).
  17. Individual has used sleep aid medications, supplements, and/or products, including antihistamines, within 2 weeks of visit 1 (week -1) A washout prior to screening is allowed).
  18. Individual has a known allergy to any ingredients in the study products.
  19. Individual is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to use of a medically approved form of contraception throughout the study period.
  20. Subject has an active infection or has used antibiotics within 5 d of any clinic visit. For those with an active infection and/or using antibiotics, subjects must wait at least 5 d after the infection resolves or antibiotic use is complete. The test period will be extended for completion in these cases.
  21. Subject has been exposed to any non-registered drug product within 30 d of visit 1 (week -1).
  22. Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 55 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03562468
Other Study ID Numbers  ICMJE MB-1801
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party ChromaDex, Inc.
Study Sponsor  ICMJE ChromaDex, Inc.
Collaborators  ICMJE Midwest Center for Metabolic and Cardiovascular Research
Investigators  ICMJE Not Provided
PRS Account ChromaDex, Inc.
Verification Date July 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP